Original Article

Q10 supplementation effects on cardiac enzyme CK-MB and troponin in patients undergoing coronary artery bypass graft: a randomized, double-blinded, placebo-controlled clinical trial

Jalal Moludi¹, Seyedali Keshavarz², Ali Sadeghpour Tabaeae³, Saeid Safiri⁴, Reza Pakzad⁵*

¹Department of Biochemistry and Diet Therapy, Faculty of Nutrition, Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
²School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
³Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
⁴Managerial Epidemiology Research Center, Department of Public Health, School of Nursing and Midwifery, Maragheh University of Medical Sciences, Maragheh, Iran
⁵Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Article info

Article History:
Received: 28 September 2015
Accepted: 24 February 2016
epublished: 14 March 2016

Keywords:
CK-MB
Troponin
Coronary Artery Bypass
CO Q10

Abstract

Introduction: Coronary artery bypass surgery (CABG) is associated with ischemia-reperfusion injury and tissue damage. CoQ10 as an antioxidant has an important role and may have cardio-protective effects after myocardial dysfunction and CABG. We aimed to evaluate whether CoQ10 has a myocardial cardio protective impact on cardiac biomarkers after CABG.

Methods: In this double-blind study, 80 patients with coronary artery disease (CAD) who underwent CABG surgery were divided into intervention and control groups and received Q10 supplement or placebo, respectively. The surgical characteristics of the patients in the two groups were similar. The intervention group received 150 mg of Q10 supplement per day for 7 days before the surgery. The control group received placebo capsule. After operation the inter- and intra-group blood levels of CK-MB and troponin, before and after supplementation and 12 hours after the CABG, and postoperative outcomes such as intensive care unit (ICU) stay and hospital stay were compared.

Results: In this study, 40 subjects were located in each group. The participation rate was 97.5% and men and women accounted for 52.5% and 47.5% respectively. The mean age of the subjects was 58.17 ± 8.55. The two groups were not significantly different in terms of CK-MB (P=0.384) and troponin (P=0.115). In the end, no interaction was observed between the intervention and time on CK-MB (P=0.095) and troponin (P=0.198) variables.

Conclusion: Q10 supplementation 7 days before surgery was not effective in reducing CK-MB and troponin after CABG.

Please cite this article as: Moludi J, Keshavarz S, Sadeghpour Tabaeae A, Safiri S, Pakzad R. Q10 supplementation effects on cardiac enzyme CK-MB and troponin in patients undergoing coronary artery bypass graft: a randomized, double-blinded, placebo-controlled clinical trial. J Cardiovasc Thorac Res 2016;8(1):1-7. doi: 10.15171/jcvtr.2016.01.

Introduction

Coronary artery bypass surgery (CABG) surgery is a high-risk procedure. Evidence indicates that cardiopulmonary bypass (CPB) leads to inflammatory response that may be responsible for some of the major complications after open-heart surgery.¹ ² Under reoxygenation condition, the blood flows back into the ischemic area after the surgery followed by the production of free radicals (e.g. superoxide anion) disrupting the production of ATP.³ Metabolic changes that occur during ischemia and cardiac myocytes, reduce glutathione system in the first line of defense against ROS in mitochondria. Reduced glutathione levels lead to the formation of ROS, oxidative stress, and increase intracellular calcium levels.⁴ Dysrhythmia after the surgery, as an indicator visible from oxidant stress during operation is considered, and can provide a basis for the comparison of strategies in protecting the heart during cardiac surgery.⁵ CK-MB and Troponin as a marker of myocardial infarction are used to measure these biomarkers to assess patients and con-
According to previous studies, a low level of troponin after the surgery is predictive of success in short and long-term. For this reason, decreases in the levels of these biomarkers could be useful. Peak plasma levels of troponin in the study of Cummins B, and others, was expressed 14 hours after the onset of acute myocardial infarction (AMI). For this reason, we also measured troponin in the first 12 hours after the surgery. It appears that during CAGB, total antioxidant capacity is significantly reduced. Coenzyme Q10, as an antioxidant can reduce free radicals and may play an effective role in reducing cardiac enzymes and complications after the surgery. The main objective of this study was to determine the effect of Q10 supplements on the level of CK-MB and troponin levels after elective coronary artery bypass graft.

Materials and methods

Design and setting
This was a double-blind randomized clinical trial implemented in Shahid Rajai Heart Center in 2013 through a parallel design.

Sample size
Considering the type of analysis, effect size = 0.25, power = 0.80, a = 0.05 and the fact that the two groups were studied the total number of required samples was determined 82 using the software G-power.

Inclusion and exclusion criteria
All patients who qualified elective CAGB surgery based on angiography were included in the study. Also, patients who have experience of warfarin use, antioxidant intake, hybrid surgery, creatinine greater than 1.5 and advance heart failure were excluded from the present study.

Sampling and random assignment
At first, 100 patients candidate for CAGB surgery admitted to hospital were selected with a daily visit to the different wards of Shahid Rajai hospital and according to the study inclusion and exclusion criteria, 88 of them were selected and given a full explanation about the goals of the study and were asked to offer informed consent. Six people refused to consent after hearing explanations and were excluded from the study (Figure 1). Finally, 82 patients were assigned to experimental and control groups using randomized block method in size of 4. To create random blocks, RAS (Research Analysis and Statistics) software was used.

Intervention and blinding
The considered intervention was a supplement called Q10 which was a vitamin-like enzyme and can reduce the CK-MB and troponin enzymes. This supplement was made in 50-mg capsules by the Elixir Pharmaceuticals, Inc. Eighty-two boxes were used in this study and 41 of which had Label A and contained 50 mg Q10 supplement capsules and 41 other capsules had Label B and contained similar and empty capsules as placebo which were made by the same company. After determining patients and arranging blocks, boxes were given to patients and given that the study was double blinded, patient and the nurse who was the responsible for the hospital ward were unaware from the contents of the boxes and capsules.

For the intervention group, Q10 supplement was daily given to patients as 50-mg capsules for seven days and the control group was given capsules as placebo with identical shape and without any drug content (only a similar coating).

Procedure
Standard intravenous anesthesia (with 10 mg oral lorazepam) was done. Similar standard surgical techniques was done in all cases. Sternotomy was performed from the middle part of the sternum. In addition, grafting one of internal thoracic arteries with 1-5 peripheral veins from lower limbs was considered in each case. CPB was prepared and an anastomosed with proximal area with moderate hypothermia. After surgery, patients were transferred to the intensive care unit (ICU) and separated from mechanical ventilation with the following criteria: Hemodynamic stability, ambient temperature over 36°C, cooperation, lack of major bleeding and acceptable arterial blood gases.

Measurements
The variables of age, gender, average graft time, average time of cross clamp and graft and pre-operation ejection fraction were measured as basic variables. Venous blood samples were taken from the antecubital without tourniquet for cardiac enzyme levels. For the measurement of outcome variables such as CK-MB and Troponin (By chemiluminescence: bioMérieux launches VIDAS® Troponin I Ultra kit is made in France and the MB kit Audit Diagnostics facility in Cork, Ireland), blood samples of all the patients were measured in terms of these enzymes in three occasions before beginning supplements and seven days after supplementation and twelve hours after surgery and were compared on this basis. All patients were transferred to ICU after surgery.

Statistical analysis
Data were analyzed using SPSS version 16. To study the normality of data distribution, Kolmogorov-Smirnov test was used. For comparing baseline data, t test and chi-square tests were used and to compare the effect of supplementation during the three occasions one-way repeated measure ANOVA was used. Moreover, Bonferroni test was used for pair-wise comparisons. Data are expressed as mean ± SD for the quantitative and No. (%) for the categorical variables. Significance level was set at 0.05.

Results

Comparing baseline data on two groups
Given that after random allocation of subjects in the intervention group, one patient experienced Cr >1.5 and
the aneurysm. Besides, one patient in the control group was excluded because he/she experienced combinatorial surgery. Finally, 40 patients were compared in each group. Participant rate was 97.5% and no side effects were observed. All the information was measured and there was no missing in this regard. All quantitative variables were normal. The mean age of the subjects was 58.17 (SD = 8.55, range = 33-70). Forty-two patients were male (52.5%) and 38 patients (47.5%) were female. Comparing baseline variables between the two groups of intervention and control showed no significant difference of variable age between the two groups (P = 0.0836). Variable distribution of blood pressure (P = 0.115), sex (P = 0.179) and diabetes (P = 0.799) were not significantly different between the two groups. Besides, the variables bypass time (P = 0.667), cross clamp time (P = 0.621), Pre-operation (ejection fraction) (P = 0.269) and graft (P = 0.179) were not significantly different between the two groups (Table 1).

**Within subject for CK-MB and troponin variables**

Comparing the average variable CK-MB in three time measurements showed that the average variable CK-MB decreased over time and then increased so that it was (21.04 ± 8.33) at the first time, (18.89 ± 6.71) at the second time, and (32.19 ± 20.83) at the third time and the three values were significantly different (P < 0.001). Bonferroni test results used for pair-wise comparison showed that CK-MB variable at the second time is less than the

---

**Table 1. Comparison of basic variables between the two groups**

| Variable                      | Intervention (n = 40) | Control (n = 40) | P-Value |
|-------------------------------|----------------------|-----------------|---------|
| Age                           | 58.37 ± 1.25         | 57.97 ± 1.45    | 0.0836  |
| Bypass Time                   | 73.67 ± 22.13        | 71.3 ± 20.8     | 0.667   |
| Cross Clamp time              | 37 ± 13.15           | 38 ± 15.15      | 0.621   |
| Graft                         | 3.21 ± 0.84          | 3.02 ± 0.80     | 0.179   |
| Pre-operation ejection fraction| 36.75 ± 8.8          | 34.71 ± 7.07    | 0.269   |
| Hypertension                  |                      |                 | 0.115   |
| Yes                           | 21 (60)              | 14 (40)         |         |
| No                            | 19 (42.2)            | 26 (57.8)       |         |
| Sex                           |                      |                 | 0.179   |
| Male                          | 24 (57.1)            | 18 (42.9)       |         |
| Female                        | 16 (42.1)            | 22 (59.9)       |         |
| Diabetes Melitus              |                      |                 | 0.799   |
| Yes                           | 11 (52.4)            | 10 (47.6)       |         |
| No                            | 29 (48.2)            | 30 (50.8)       |         |

*Quantitative and qualitative variables were presented as mean ± SD and number (percent), respectively. Quantitative and qualitative variables were compared between two groups using independent t test and chi-square test, respectively. Significance level was considered as 0.05.*
Interventional studies of coronary artery showed that the peak level of CK-MB not only is along with higher mortality, but with a higher risk of events after surgery leading to further cost of treatment in these patients. However, trying to identify a threshold and the upper and lower limits that predict patients’ prognosis is faced with failure. According to the definition of ACC, cardiac biomarkers level (CK-MB and troponin I) is considered as more than 3 times the upper limit of normal as myocardial infarction and the range between one and three times is considered as myocardial injury. It is surely clear that the risk of side effects increases with any increase in CK-MB. Therefore, measurement of cardiac enzymes following coronary intervention is strongly recommended, and the reduced level of cardiac enzymes is along with improved surgical outcomes in the short-term and long-term, although 0.1 ng/mL troponin was used as the cutoff. Even low levels may cause myocardial injury. In this study, 0.1 ng troponins were considered as high levels (positive troponin). After CBP, troponin and CKMB levels begin to rise after six hours and two hours respectively, so we used both markers.

CoQ10 plays an important role in stabilizing the membrane while helping replenish ATP storage inside the cell. These mechanisms minimize cellular damage and a decrease in cardiac enzymes can be experienced. According to previous studies, the used dose was determined as 150 mg per day for seven days. On the other hand, according to the study, it is found that a daily dose more than 300 mg creates negative effects such as increased levels of serum LDH, that's why some studies have used excessive doses of supplements have not reported a positive effect in patients.

Various studies have indicated the effect of antioxidants in reducing cardiac enzymes level, so that Foroughinia et al study showed omega-3 positive impact in reducing the levels of cardiac enzymes. Makhija et al showed that pre-operative use of Q10 can lower levels of cardiac enzymes. Other studies have shown that Q10 supplement is effective on troponin and CK-MB enzymes after surgery, even when supplement is administered only once. Pepping noted in his study that it takes at least four days to achieve therapeutic level. That is why we raised supplementation period to seven days in this study. In a review study by Bulatao and Banez, it was shown that oral supplement Q10 in spite of providing lower surgery indices including

**Table 2. Comparing the CK-MB and troponin levels between two study groups**

| Variable | Time 1 | Time 2 | Time 3 | Total Intervention (40) | Control (40) |
|----------|-------|-------|-------|------------------------|--------------|
| CK-MB    | 21.04 ± 8.33 | 18.89 ± 6.71 | 32.19 ± 20.83 | 23.14±1.45 | 24.94±1.45 |
| Troponin | 0.072 ± 0.1 | 0.26 ± 0.48 | 0.64 ± 0.76 | 0.263±0.059 | 0.395 ± 0.059 |

The mean±SD studied variables were presented in three time points.
*Between and within subjects analyses were done using Greenhouse-Geisser test.
*Significance level was considered as 0.05.
less drainage, less hospital stay and less need for inotropic had no effect on cardiac biomarkers level. Increasing the number of grafts is directly correlated with higher levels of the enzyme. Jang et al showed in his study that increasing troponin serum levels is associated with the number of involved arteries that underwent PCI. In our study, a statistically significant difference was not observed in number of grafts. Previous studies have indicated a strong correlation between the number of grafts and graft type with increased levels of cardiac enzymes as observed in one of the studies that internal mammary artery (IMA, #32) graft was along with less increase in cardiac enzyme levels. Age and gender were also evaluated as a risk factor for elevating troponin serum levels. But no significant statistical difference was observed between the two groups, age and sex with troponin. Wiviott et al in 2004 compared the effects of gender on designed cardiac enzyme levels. It was observed that the level of CK-MB and troponin is higher in men, while inflammatory marker following AMI and angina is higher in women. In this study from among 80 cases of intervention and control at baseline, 71.3% had negative troponin (troponin larger than 0.1) and 28.7% had positive troponin and after surgery, total troponin level was 25% percent negative and 75% positive. Inter and intra group comparisons showed that Q10 supplements could not have a significant effect in reducing the levels of troponin. Although in previous studies, using some supplements such as omega-3 could have a positive effect on the number of positive troponins. In explaining why the supplement could not reduce the enzyme levels, items such as long time surgery can be cited. Because in this study, the time of surgery was more than 73 minutes, while in other studies it has been for about 49 minutes and it is obvious that whatever this period is more, the cardiac enzymes CK-MB and troponin will be higher. That is why the present study has not been able to be successful in reducing the level of cardiac enzymes. After surgery, the incidence of arrhythmia in the intervention group who received CoQ10 supplement was significantly lower compared with the control group. However, hospital stay and ICU stay were not significantly different between the two groups. Although in some studies, the effect of supplementation was seen to reduce the length of stay in the ICU and reduced drainage. According to the results obtained from a randomized double-blinded study, the prescription of Q10 supplements was not effective unlike the designers' original idea in reducing cardiac enzyme (CK-MB) and troponin after CABG.

**Limitations of the study**
The results of the present study were based on a research on a small population of patients undergoing coronary bypass surgery that may be the main reason for not observing the effect of supplementation in reducing cardiac enzyme levels. Besides, the short time of supplementation or inadequate dose of Q10 may have a significant role in the lack of impact of reducing troponin. Moreover the limitations of this study include lack of body antioxidant levels during the period mentioned, in fact, our blindfold, just looked at the effect of antioxidant supplements That's why more studies are needed in this regard.

**Acknowledgments**
We would like to offer our appreciation and thanks to Tehran Rajae heart hospital nurses and doctors who have supported us.

**Ethical issues**
After obtaining the ethics code of Tehran University of Medical Sciences (25555-161-01-93) and registration at Iranian Registry of Clinical Trials (IRCT ID: 2013122815957N1) was conducted according to the Helsinki protocol.

**Competing interests**
None.

**References**
1. Kunt AS, Selek S, Celik H, Demir D, Erel O, Andac MH. Decrease of total antioxidant capacity during
coronary artery bypass surgery. Mt Sinai J Med 2006; 73(5): 777-783.
2. Kurt AS, Andac MH. Decrease of total antioxidative capacity in developed low cardiac output syndrome. Oxid Med Cell Longev 2012; 2012: 356301. doi: 10.1155/2012/356301.
3. Han Y, Tuccio B, Lauricella R, Rockenbauer A, Zweier JL, Villamena FA. Synthesis and spin-trapping properties of a new spiroacetyl nitronyl nitrone. J Org Chem 2008; 73(7): 2533-2541. doi: 10.1021/jo0702434u.
4. Jones RD, Hancock JT, Morice AH. NADPH oxidase: a universal oxygen sensor? Free Radic Biol Med 2000; 29(5): 416-424. doi: 10.1016/S0891-5849(00)00320-8.
5. Bidar E, Kramer S, Maesen B, Maessen J, Schotten U. Post-operative atrial fibrillation–pathophysiology, treatment and prevention. J Atr Fibrillation 2013;5:6.
6. Guzy PM. Creatine phosphokinase-MB (CPK-MB) and the diagnosis of myocardial infarction. West J Med 1977;127(6):455-460.
7. Adams JE 3rd, Sircad GA, Allen BT, Bridwell KH, Lenke LG, Dávila-Román VG, et al. Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. N Engl J Med 1999;340(10):670-674. doi: 10.1056/NEJM1999033131001003.
8. Li F, Clark R, Versace V, Newman P. The association between Point-of-Care testing of Troponin and the management of patients with chest pain suspected of acute coronary syndrome: a systematic review protocol. JBI Database System Rev Implement Rep 2014;12(3):99-112.
9. Sugino K, Dohi K, Yamada K, Kawasaki T. Changes in the levels of endogenous antioxidants in the liver of mice with experimental endotoxemia and the protective effects of the antioxidants. Surgery 1989; 105(2pt 1):200-206.
10. Rosenfeldt F, Marasco S, Lyon W, Woyuk M, Sheeran F, Bailey M, et al. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac Cardiovasc Surg 2005; 129(1): 25-32. doi: 10.1016/j.jtcvs.2004.03.034.
11. Makhija N, Sendasgupta C, Kiran U, Lakshmy R, Hote MP, Choudhary SK, et al. The role of oral coenzyme Q10 in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2008;22(6): 832-839. doi: 10.1053/j.jvca.2008.03.007.
12. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G* Power 3.1: Tests for correlation and regression analyses. Behav Res Methods 2009;41(4):1149-1160. doi: 10.3758/BRM.41.4.1149.
13. Cleveland JC Jr, Shroyer AL, Chen AY, Peterson E, Grover FL. Off-pump coronary artery bypass grafting decreases risk-adjusted mortality and morbidity. Ann Thorac Surg 2001;72(4):1282-1288. doi:10.1016/S0003-4975(01)03006-5.
14. Puskas JD, Williams WH, Duke PG, Staples JR, Glas KE, Marshall JJ, et al. Off-pump coronary artery bypass grafting provides complete revascularization with reduced myocardial injury, transfusion requirements, and length of stay: a prospective randomized comparison of two hundred unselected patients undergoing off-pump versus conventional coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003;125(4):797-808. doi:10.1067/mct.2003.324.
15. Ong SB, Subryan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation 2010;121(18):2012-2022. doi: 10.1161/CIRCULATIONAHA.109.906610.
16. Hearse DJ, Stewart DA, Braimbridge MV. Myocardial protection during ischemic cardiac arrest. The importance of magnesium in cardioplegic infuses. J Thorac Cardiovasc Surg 1978;75(6):877-885.
17. Menasche P, Groussset C, Gauduel Y, Piwnica A. A comparative study of free radical scavengers in cardioplegic solutions. Improved protection with peroxidase. J Thorac Cardiovasc Surg 1988;92(2):264-271.
18. Kim LJ, Martinez EA, Faraday N, Dorman T, Flesher LA, Perler BA, et al. Cardiac troponin I predicts short-term mortality in vascular surgery patients. Circulation 2002;106(18):2366-2371. doi: 10.1161/01.CIR.0000036016.52396.BB.
19. Alexander JH, Sparapani RA, Mahaffey KW, Decker JW, Newby LK, Ohman EM, et al. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. JAMA 2000;283(3):347-353. doi: 10.1001/jama.283.3.347.
20. Giannitsis E, Möller-Bardorff M, Lehrke S, Wiegand U, Tölg R, Weidtmann B, et al. Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction. Circulation 2001; 104(6):630-635. doi: 10.1161/hc3101.093863.
21. Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1999;96(8):2641-2648. doi: 10.1161/01.CIR.96.8.2641.
22. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36(3):959-969. doi: 10.1016/S0735-1077(00)00804-4.
23. Costa MA, Carere RG, Lichtenstein SV, Foley DP, de Valk V, Lindenboom W, et al. Incidence, predictors,
and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation 2001;104(22):2689-2693. doi: 10.1161/hc4701.099789

24. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. J Am Coll Cardiol 1999;33(1):88-96. doi: 10.1016/S0735-2001.34(5):486-492.

25. Kathiresan S, Servoss SJ, Newell JB, Trani D, MacGillivray TE, Lewandrowski K, et al. Cardiac troponin T elevation after coronary artery bypass grafting is associated with increased one-year mortality. Am J Cardiol 2004;94(7):879-881. doi: 10.1016/j.amjcard.2004.06.022.

26. Landesberg G, Slatz V, Akopnik I, Wolf YG, Mayer M, Berlatzky Y, et al. Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. J Am Coll Cardiol 2003;42(9):1547-1554. doi: 10.1016/j.jacc.2003.05.001.

27. Chan MY, Pronovost PJ. Clinical utility of biomarkers in myocardial injury. Curr Opin Anaesthesiol 2004;17(1):49-55. doi: 10.1097/01.aco.0000114688.04870.d2

28. Wu ZK, Pehkonen E, Laurikka J, Kaukinen L, Honkelen EL, Kaukinen S, et al. Protective effect of unstable angina in coronary artery bypass surgery. Scand Cardiovasc J 2000;34(5):486-492. doi: 10.1080/140174300750064657.

29. Kato T, Yoneda S, Kako T, Koketsu I, Fujinami T. Reduction in blood viscosity by treatment with coenzyme Q10 in patients with ischemic heart disease. Int J Clin Pharmacol Ther Toxicol 1990;28(3):123-126.

30. Tiano L, Belardinelli R, Carneyali P, Principi F, Seddaiu G, Littarru GP. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Heart J 2007;28(18):2249-2255. doi: 10.1093/eurheartj/ehm267.2249-2255.

31. Bulatao DP, Banez C. Effect of Preoperative Treatment of oral coenzyme Q10 on reperfusion arrhythmias and myocardial protection in patients Undergoing Coronary Artery Bypass Graft (CABG). J Arrhythm 2011;27:PE4-02. doi: 10.4020/jhrs.27.PE4_020

32. Sunamori M, Tanaka H, Maruyama T, Sultan I, Sakamoto T, Suzuki A. Clinical experience of coenzyme Q10 to enhance intraoperative myocardial protection in coronary artery revascularization. Cardiovasc Drugs Ther 1991;5:297-300. doi: 10.1007/BF00054751.

33. Gaby AR. The role of coenzyme Q10 in clinical medicine: Part I. Alt Med Rev 1996;1(1):11-17.

34. Foroughinia F, Salamzadeh J, Namazi MH. Protection from procedural myocardial injury by omega-3 polyunsaturated fatty acids (PUFAs): is related with lower levels of creatine kinase-MB (CK-MB) and troponin I. Cardiovasc Ther 2013;31(5):268-273. doi: 10.1111/1755-5922.12016.

35. Pepping J. Coenzyme Q10. Am J Health Syst Pharm 1999;56(6):519-521.

36. Jang SW, Rho TH, Kim DB, Cho EJ, Kwon BJ, Park HJ, et al. Optimal antithrombotic strategy in patients with atrial fibrillation after coronary stent implantation. Korean Circ J 2011;41(10):578-582. doi: 10.4070/kcj.2011.41.10.578.

37. Berger A, MacCarthy PA, Siebert U, Carlrix S, Wijns W, Heyndrickx G, et al. Long-term patency of internal mammary artery bypass grafts relationship with preoperative severity of the native coronary artery stenosis. Circulation 2004;110(11):II-36-40. doi: 10.1161/01.CIR.0000141256.05740.69.

38. Wiviot SD, Canyon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non–ST-elevation myocardial infarction a TACTICS-TIMI 18 (treat angina with aspirat and determine cost of therapy with an invasive or conservative strategy–thrombolysis in myocardial infarction 18) substudy. Circulation 2004;109(5):580-586. doi: 10.1161/01.CIR.0000109491.66226.26.

39. Veljovic M, Popadic A, Vukic Z, Ilic R, Trifunovic Z, Antunovic M, et al. Myocardial protection during elective coronary artery bypass grafting by pretreatment with omega-3 polyunsaturated fatty acids. Vojnosanit Pregl 2013;70(5):484-492. doi: 10.2298/VSP1305484V.

40. Tomai F, De Paulis R, Penta de Peppo A, Colagrande L, Caprara E, Polisca P, et al. Beneficial impact of isofurane during coronary bypass surgery on troponin I release. G Ital Cardiol 1999;29(9):1007-1014.

41. Källner G, Lindblom D, Forssell G, Kallner A. Myocardial release of troponin T after coronary bypass surgery. Scand J Thorac Cardiovasc Surg 1994;28(2):67-72. doi: 10.3109/14017439409100165.

42. Farazi A, Sofian M, Jabbarsial M, Nayebzadeh B, Coenzyme Q10 Administration in Community-Acquired Pneumonia in the Elderly. Iran Red Crescent Med J 2014;16(12):e18852. doi: 10.5812/ircmj.18852.

43. Coppadora O, Bera L, Kumar A, Yamada M, Pinciroti R, Bittner E, et al. Plasma levels of Coenzyme Q10 are reduced in critically ill patients as compared to healthy volunteers and correlate with age. Crit Care 2012;16:P154. doi: 10.1186/cc10761.